. Author manuscript; available in PMC: 2022 Sep 1.

Published in final edited form as: Clin Chim Acta. 2021 May 28;520:16–22. doi: 10.1016/j.cca.2021.05.022

Table 3.

Reclassification of eGFR category upon adoption of the CKD-EPI equation without the race correction factor (CKD-EPI_NoRace) in the full cohort.^a

MDRD (mL/min/1.73m²), N	CKD-EPI_NoRace (mL/min/1.73m²), N (%)
MDRD (mL/min/1.73m²), N	≥ 90 (N=132,957)	60–89 (N=80,940)	45–59 (N=15,298)	30–44 (N=7,119)	15–29 (N=3,043)	< 15 (N=2,403)
≥ 90 (N=108,503)		5,887 (5.43)

60–89 (N=102,494)	30,341 (29.60)		1,387 (1.35)

45–59 (N=18,251)		4,287 (23.49)		857 (4.70)

30–44 (N=7,234)			804 (11.11)		307 (4.24)

15–29 (N=2,973)				139 (4.68)		129 (4.34)

< 15 (N=2,305)					31 (1.34)

The reclassification rate was calculated by dividing the number of patients who were classified into a different category when eGFR was calculated with the CKD-EPI_NoRace equation compared to the MDRD equation by the total number of patients in the original category when calculated by the MDRD equation.